Article

More Research is Needed For Allergen Reduction Guidelines

After a thorough analysis of all controlled studies, no strong clinically significant evidence was observed for any individual or multicomponent intervention.

Brian F. Leas, MS, MA

A wide variety of interventions designed to reduce allergens have been studied in clinical trials examining asthma outcomes, but the likelihood of asthma increases with the greater the complexity of the environment. Factors are vast and include an expanding list of environmental factors that come with a low-income house that must be considered such as greater numbers of cockroaches, other pests, less maintenance of carpeting, bedding, and much more.

Extensive meta-analysis of 59 randomized controlled trials and 8 non-randomized controlled trials was presented at the 2018 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in Orlando, Florida, by authors Brian F. Leas, MS, MA and Senior Research Analyst together with Professor Andrea J. Apter, MD, both from the University of Pennsylvania’s Center for Evidence-based Practice.

After a thorough analysis of all controlled studies, their conclusion was largely negative, with no strong clinically significant evidence observed for any individual or multicomponent intervention.

There were some multicomponent interventions that did show some benefit in reducing allergens including air purification multicomponent context, carpet removal multicomponent, HEPA filter, vacuum multicomponent, mattress cover multicomponent, pest control multicomponent, but absolutely none of the studies to date provided strong clinical control of asthma.

What’s more, Leas pointed out, there are costs and potential downsides to any of these strategies that are not really considered within any of the studies. When queried, Apter said that she is not a fan of purchasing special mattress covers when money is commonly reserved in asthmatic environments, and so often changing mattress covers has been shown to make no difference.

Apter noted that the evidence is inconclusive “because of a lack of studies.”

Researchers noted there were too many limitations — while there were several placebo-controlled studies, for example, involving changing mattress covers that were actually permeable, there were no studies the directly compared two different interventions.

Severity was not considered in most studies, so researchers do not know whether they were dealing with mild or severe asthma. Intervention adherence monitoring was not always clear in most studies.

More research is needed. Apter explained that even if they are able to clearly and reproducibly reduce suspected allergens, it remains possible that this will still have no clinical benefit in the control of asthma and associated exacerbations.

When asked what their guideline recommendation is, Apter expressed uncertainty. Because mattress covers often do not provide any benefit, so she is not openly open for them. She does believe that cost should always be a consideration and that she just cannot make a strong recommendation one way or another based on the current analysis.

She stated that her bias is that she would like to know more about the home and personal situation of the individual patient(s). Leas agreed that the downsides to any recommendations need more attention and consideration as well.

Click here to sign up for more MD Magazine content and updates.

Related Coverage >>>

How to Identify Gene-Modifiable Environment Risk Factors for Eosinophilic Esophagitis

Telemedicine's Impact on Allergy and Asthma Through Monitoring and Adherence

Switching to Mepolizumab Improved Uncontrolled Asthma for Patients on Omalizumab

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
© 2024 MJH Life Sciences

All rights reserved.